genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide.
The last earnings update was 195 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
genOway. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
genOway's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as genOway has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare genOway's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare genOway's earnings growth to the Germany market average as no estimate data is available.
Unable to compare genOway's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if genOway is high growth as no earnings estimate data is available.
Unable to determine if genOway is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
genOway's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Christian Grenier serves as the Chief Executive Officer at BioVision. Mr. Grenier was an Operating Partner at Advent International Corporation. He joined Advent on March 10, 2010 to advice on investment opportunities across the healthcare and speciality chemicals sector. Previously, he spent 13 years within the Aventis S.A./Rhône-Poulenc group where Mr. Grenier held three Executive Management roles in various divisions including specialty chemicals, animal and agro care. Previously, He served as Chief Executive Officer at UroGene, S.A. Mr. Grenier began his career with McKinsey & Company, Inc. as a Stategy Consultant and then Airbus Industries. He co-founded the biotechnology company Urogène sold seven years later to the Pierre Fabre Group. He serves as the Chairman of GenOway S.A and also serves as its Chief Executive Officer since May 2019. He serves as Chairman of Supervisory Board of UroGene, S.A. Mr. Grenier also serves as Non-Executive Chairman for several industrial and biotech companies, including Laboratoire Delpharm, Cytomix System, Watchfrog and Neorphys SAS. Mr. Grenier graduated fom ESCP and INSEAD.
Insufficient data for Christian to compare compensation growth.
Insufficient data for Christian to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Chairman & CEO
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the genOway board of directors is less than 3 years, this suggests a new board.
Board of Directors
Robert Claude Leon
Chairman & CEO
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.